Workflow
AbbVie(ABBV)
icon
Search documents
U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result
The Motley Fool· 2025-05-24 08:11
There's little doubt these pharmaceutical companies' costs will soon be rising at least a little.The tariff war the U.S. is waging against most of the world stabilized somewhat earlier this month. But let's face facts -- it could easily flare up again. President Donald Trump appears quite committed to the idea of leveraging America's economic dominance, and no industry is immune to this dynamic.One could argue, however, that the pharmaceutical industry is especially vulnerable. Although the 25% import tarif ...
Levi & Korsinsky Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ABBV
Prnewswire· 2025-05-23 09:45
NEW YORK, May 23, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all persons or entities that: (a) sold or otherwise disposed of the publicly-traded com ...
Levi & Korsinsky Notifies Shareholders of Cerevel Therapeutics Holdings, Inc. (ABBV) of a Class Action Lawsuit and an Upcoming Deadline
GlobeNewswire News Room· 2025-05-22 17:47
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all persons or entities that: (a) sold or otherwise disposed of the publicly-trade ...
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV
Prnewswire· 2025-05-22 09:45
Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cerevel Therapeutics Holdings, Inc. regarding a class action lawsuit related to alleged misleading statements and omissions during a secondary stock offering, which may have artificially deflated the stock price prior to a merger announcement with AbbVie Inc. [1][2] Group 1: Allegations and Impact - Cerevel's October 16, 2023 secondary stock offering documents allegedly omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, leading to an artificial deflation of Cerevel's stock price [2] - Bain Capital, Cerevel's controlling shareholder, reportedly acquired shares at this artificially depressed price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share on December 6, 2023 [2] - The January 18, 2024 Proxy statement from Cerevel is claimed to have misled investors regarding the nature and timing of AbbVie's interest in the company [2] Group 2: Class Action Details - The class period for the lawsuit includes shareholders who sold or disposed of Cerevel stock from October 11, 2023, to August 1, 2024, and those who held shares as of January 8, 2024, entitled to vote on the merger [1] - The deadline for shareholders to register for the class action and seek lead plaintiff status is June 3, 2025, with no cost or obligation to participate [3] - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's status [3]
69 May Aristocrats: Buy 1 Of 38 "Safer" Dividend Dogs
Seeking Alpha· 2025-05-20 19:55
S&P made three additions to the Dividend Aristocrats in January 2025: Erie Indemnity ( ERIE ), Eversource Energy ( ES ), and FactSet Research Systems ( FDS ) were tapped for inclusionWrap Up The S&P500 Aristocrat Dividend DogsClick here to subscribe to The Dividend Dogcatcher. Get more information and the follow-up portfolios related to this article.Catch A Dog On Facebook the morning of almost every NYSE trade day on Facebook/Dividend Dog Catcher, A Fredrik Arnold live video highlights a portfolio candidat ...
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class Action - ABBV
Prnewswire· 2025-05-20 09:45
NEW YORK, May 20, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all persons or entities that: (a) sold or otherwise disposed of the publicly-traded com ...
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc. (ABBV) Shareholders
GlobeNewswire News Room· 2025-05-19 17:30
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all persons or entities that: (a) sold or otherwise disposed of the publicly-trade ...
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact The Gross Law Firm about pending Class Action - ABBV
Prnewswire· 2025-05-19 17:04
NEW YORK, May 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cerevel-therapeutics-holdings-inc-loss-submission-form/?id=148824&from=4 ...
Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.
The Motley Fool· 2025-05-18 16:05
Core Insights - The article discusses three dividend-paying stocks that are currently facing challenges regarding their dividend sustainability, highlighting the importance of dividend growth for long-term investment returns [1][19]. Company Summaries AbbVie - AbbVie is a pharmaceutical company with a market capitalization of $300 billion, known for drugs like Skyrizi and Botox [3]. - The stock has declined by 16% year-to-date and offers a quarterly dividend of $1.64 per share, resulting in an annual yield of 3.5% [3]. - AbbVie has a concerning payout ratio of 266%, indicating potential risks to its dividend payments [4]. - Sales of Humira, a key drug, have dropped by 51% to $1.1 billion in fiscal Q1 2025 compared to the previous year, contributing to a 69% decline in net income over the trailing 12 months [5]. - The company's net debt has increased by 24% over the past two years to $64.7 billion, raising doubts about the future of its dividend [6]. - However, AbbVie's next-generation drugs, Skyrizi and Rinvoq, generated $5.1 billion in fiscal Q1 2025, a 65% increase year-over-year, with expectations of continued growth [7]. Medtronic - Medtronic is a medical device company with a focus on cardiac devices and surgical tools, currently down 37% from its 2021 highs [8]. - The company has paid and raised its dividend for 47 consecutive years, with a current quarterly dividend of $0.70 per share, yielding 3.3% annually [9]. - Medtronic's payout ratio stands at 84.7%, with a reported net income of $1.29 billion in fiscal Q3 2024, reflecting a 2% decline year-over-year [10]. - Despite revenue reaching all-time highs, net income has not significantly grown in a decade, partly due to the company's extensive acquisition strategy [11]. - Medtronic holds $18.6 billion in net debt, with servicing costs of $757 million over the past year, although it has reduced debt by 8% from recent highs [12][13]. Pfizer - Pfizer is a well-known pharmaceutical company with a history of 176 years, recently recognized for its COVID-19 vaccine [15]. - The company offers a quarterly dividend of $0.43 per share, yielding 7.6%, but its stock has fallen 63% from pandemic highs [16]. - Pfizer's payout ratio is 121.5%, raising concerns about its ability to maintain dividend increases for the 17th consecutive year [16]. - The company reported an 8% decline in revenue for Q1 2025, with total revenue of $13.7 billion, down from $14.9 billion in Q1 2024, largely due to a 76% drop in sales of its COVID-19 product, Paxlovid [17]. - Pfizer has averaged over $10 billion in R&D spending annually, while also managing $44 billion in net debt, which it has reduced by 31% in less than a year [18].
3 Magnificent Stocks That Are Passive Income Machines
The Motley Fool· 2025-05-17 10:40
Core Viewpoint - The article highlights three dividend stocks—Abbott Laboratories, AbbVie, and Johnson & Johnson—as excellent options for passive income, emphasizing their strong dividend histories and solid business fundamentals. Group 1: Abbott Laboratories - Abbott Laboratories has a long history of dividend payments, dating back to 1924, and has increased its dividend for over 50 consecutive years [4] - The company currently pays a quarterly dividend of $0.59, which has risen by 146% over the past decade, averaging a compound annual growth rate of 9.4% [5] - Abbott's diverse operations across nutrition, diagnostics, pharmaceuticals, and medical devices contribute to its stability, with over $40 billion in revenue for the past four years and strong free cash flow of $6.7 billion [6][7] Group 2: AbbVie - AbbVie, spun off from Abbott in 2013, has maintained a strong dividend increase streak for 53 consecutive years, with a forward dividend yield of 3.64% [8] - The company has strategically invested in R&D and acquisitions, notably Allergan in 2020, to offset the decline in sales from its key drug Humira, which lost U.S. patent exclusivity in 2023 [9][10] - AbbVie's new drugs, Rinvoq and Skyrizi, are projected to generate combined sales of $31 billion by 2027, surpassing Humira's peak sales [10] Group 3: Johnson & Johnson - Johnson & Johnson is a leading healthcare company with a strong pharmaceutical business and a solid financial foundation, evidenced by its AAA credit rating from S&P Global [12] - The company has increased its dividends for 62 consecutive years, positioning it among the elite Dividend Kings, and is expected to continue this trend despite facing legal and regulatory challenges [13] - The defensive nature of the healthcare industry suggests that Johnson & Johnson will remain resilient during economic downturns, making it a strong choice for income-seeking investors [11]